Clinical effect of mometasone furoate nasal spray combined with montelukast in the treatment of children with obstructive sleep apnea hypopnea syndrome
10.3760/cma.j.issn.1008-6706.2019.21.005
- VernacularTitle: 糠酸莫米松鼻喷剂联合孟鲁司特钠治疗儿童阻塞性睡眠呼吸暂停低通气综合征的临床效果探讨
- Author:
Qian WU
1
;
Xiaohua PAN
Author Information
1. Department of Otolaryngology, the People's Hospital of Jinhua, Jinhua, Zhejiang 321000, China
- Publication Type:Journal Article
- Keywords:
Sleep apnea, obstructive;
Glucocorticoids;
Leukotriene antagonists;
Tonsillectomy;
Adenoidectomy;
Polysomnography;
Blood gas monitoring, transcutaneous;
Ventilation-perfusion ratio;
Children
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(21):2578-2582
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical effect of mometasone furoate nasal spray combined with montelukast in the treatment of children with obstructive sleep apnea hypopnea syndrome (OSAHS), and to analyze its feasibility and clinical application value.
Methods:From August 2017 to March 2019, 64 children with OSAHS who were treated in the People's Hospital of Jinhua were selected in the study.According to the random number table method, they were divided into the observation group and the control group, with 32 cases in each group.The observation group was treated with mometasone furoate nasal spray combined with montelukast for 12 weeks.The control group was treated with surgical treatment to remove hypertrophic tonsils and/or adenoids.The clinical symptom scores, polysomnography(PSG) monitoring index, adenoid and tonsil size index, and the efficacy after 12 weeks of treatment were compared between the two groups.
Results:There were no statistically significant differences in symptom scores and minimum arterial oxygen saturation(LSaO2) between the two groups before treatment(all P>0.05). After treatment, the symptom scores and LSaO2 of the control group were (1.90±0.53)points and (94.74±1.54)%, respectively, which of the observation group were (4.00±1.50)points and (85.34±10.57)%, respectively, the differences between the two groups were statistically significant(t=-7.416, 4.972, all P<0.05). There were statistically significant differences in the apnea hypopnea index(AHI) and obstructive apnea index(OAI) between the two groups(all P<0.05). After treatment, the A/N of the adenoids in the observation group was significantly decreased, and the difference in the tonsil classification was statistically significant(Z=-2.602, P<0.05). The effective rate of the observation group was 56.25%(18/32), which was significantly lower than that of the control group [100.00%(32/32)], the difference was statistically significant(χ2=17.920, P<0.05).
Conclusion:In summary, non-surgical treatment can alleviate OSAHS-related symptoms, reduce the size of tonsils and adenoids, and achieve the purpose of remission or cure.Non-surgical treatment can be selected when patients' families are reluctant to choose surgical treatment.
